Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
With the acquisition of Swiss healthcare AI specialist SimplicityBio, Precision for Medicine can offer new features in its QuartzBio multiomic data integration platform.
The firm will use the funds to improve market entry and expedite development of its artificial intelligence-based software that analyzes single-cell data.
The company has begun piloting the software, which is targeted towards bioinformatics companies and clinical laboratories, with early adopters ahead of the planned launch.
